This article discusses the use of artificial intelligence in precision oncology, particularly in understanding individual tumor mechanisms and aiding clinical decision-making. Dr. Xinghua Lu, with extensive experience in medicine and biomedical informatics, will present research on individualized Bayesian causal inference methods for investigating oncogenic mechanisms. These methods aim to provide clinical decision support at the cellular, tumor, and patient levels. Why it matters: AI-driven precision oncology can enable more personalized and effective cancer treatments, improving patient outcomes in the region and globally.
MBZUAI researchers are refining AI techniques to improve cancer diagnosis for colorectal and breast cancer, both common in the Middle East. They are using "few-shot tissue image generation," in which AI generates data for training AI models to recognize lesions, addressing the challenge of limited training data. The developed framework improves the efficiency of radiologists in breast cancer diagnosis, leading to better detection of breast lesions and timely treatment interventions. Why it matters: These advancements in AI-aided diagnostics can lead to earlier and more accurate cancer detection, ultimately improving patient outcomes in the region and beyond.
KAUST's Sciencetown podcast episode 23 features researcher Dana Al-Sulaiman discussing portable biosensing technologies for cancer detection. These devices aim to enable liquid biopsies for early screening and personalized treatment. The biosensors gather clinical information from biological samples to inform clinical decisions. Why it matters: This research can advance non-invasive diagnostics and personalized medicine in the region.
KAUST alumnus Dimitrios Kleftogiannis (Ph.D. '16) is now a cancer researcher at the University of Bergen, Norway, using bioinformatics to study liquid biopsies for cancer research. He transitioned from computer science to bioinformatics after his Ph.D. and was inspired by Prof. Mel Greaves at the Institute of Cancer Research in London. Why it matters: This highlights the impact of interdisciplinary training at KAUST and its alumni's contributions to applying AI and computational methods to advance healthcare research.
An AI tool has reportedly been developed that can detect pancreatic cancer up to three years before a clinical diagnosis. This finding, based on a new study, was highlighted in a report by The National. The tool aims to significantly improve early detection capabilities for a challenging disease. Why it matters: Early and accurate detection of pancreatic cancer could lead to earlier interventions and substantially improve patient outcomes and survival rates.
KAUST researchers developed a statistical approach to improve the identification of cancer-related protein mutations by reducing false positives. The method uses Bayesian statistics to analyze protein domain data from tumor samples, accounting for potential errors due to limited data. The team tested their method on prostate cancer data, successfully identifying a known cancer-linked mutation in the DNA binding protein cd00083. Why it matters: This enhances the reliability of cancer research at the molecular level, potentially accelerating the discovery of new therapeutic targets.